

**Experiment Number:** 99009 - 02  
**Test Type:** 90-DAY  
**Route:** GAVAGE  
**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Myristicin  
**CAS Number:** 607-91-0

**Date Report Requested:** 12/09/2016  
**Time Report Requested:** 13:55:48  
**First Dose M/F:** 01/23/09 / 01/22/09  
**Lab:** BAT

F1\_M3\_Rev.2

**NTP Study Number:** C99009  
**Lock Date:** 04/22/2010  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 3.0.2.3\_002  
**PWG Approval Date:** 05/22/2012

Experiment Number: 99009 - 02

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 12/09/2016

Time Report Requested: 13:55:48

First Dose M/F: 01/23/09 / 01/22/09

Lab: BAT

| B6C3F1 MICE MALE | 0 mg/kg | 10 mg/kg | 30 mg/kg | 100 mg/kg | 300 mg/kg | 600 mg/kg |
|------------------|---------|----------|----------|-----------|-----------|-----------|
|------------------|---------|----------|----------|-----------|-----------|-----------|

**Disposition Summary**

|   |           |           |           |           |           |           |
|---|-----------|-----------|-----------|-----------|-----------|-----------|
| <b>Animals Initially In Study</b>       | <b>10</b> | <b>10</b> | <b>10</b> | <b>10</b> | <b>10</b> | <b>10</b> |
| <b>Early Deaths</b>                     |           |           |           |           |           |           |
| <b>Survivors</b>                        |           |           |           |           |           |           |
| <b>Terminal Sacrifice</b>               | <b>10</b> | <b>10</b> | <b>10</b> | <b>10</b> | <b>10</b> | <b>10</b> |
| <b>Animals Examined Microscopically</b> | <b>10</b> | <b>10</b> | <b>10</b> | <b>10</b> | <b>10</b> | <b>10</b> |

## ALIMENTARY SYSTEM

|  |         |      |      |         |           |           |
|--|---------|------|------|---------|-----------|-----------|
| Esophagus                              | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Gallbladder                            | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Intestine Large, Cecum                 | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Intestine Large, Colon                 | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Intestine Large, Rectum                | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Intestine Small, Duodenum              | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Intestine Small, Ileum                 | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Intestine Small, Jejunum               | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Liver                                  | (10)    | (10) | (10) | (10)    | (10)      | (10)      |
| Fatty Change                           |         |      |      | 8 (80%) | 5 (50%)   | 10 (100%) |
| Centrilobular, Hepatocyte, Hypertrophy |         |      |      |         | 10 (100%) | 10 (100%) |
| Hepatocyte, Necrosis                   |         |      |      |         | 1 (10%)   | 10 (100%) |
| Hepatocyte, Necrosis, Focal            | 1 (10%) |      |      |         |           |           |
| Oval Cell, Hyperplasia                 |         |      |      |         |           | 10 (100%) |
| Pancreas                               | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Salivary Glands                        | (10)    | (0)  | (0)  | (0)     | (0)       | (10)      |
| Stomach, Forestomach                   | (10)    | (10) | (10) | (10)    | (10)      | (10)      |
| Inflammation, Chronic                  |         |      |      |         | 2 (20%)   | 4 (40%)   |
| Ulcer                                  |         |      |      |         |           | 2 (20%)   |
| Epithelium, Hyperkeratosis             |         |      |      |         | 2 (20%)   | 3 (30%)   |
| Epithelium, Hyperplasia                |         |      |      |         | 1 (10%)   | 3 (30%)   |
| Epithelium, Inflammation, Suppurative  |         |      |      |         |           | 4 (40%)   |
| Stomach, Glandular                     | (10)    | (10) | (10) | (10)    | (10)      | (10)      |
| Epithelium, Atrophy                    |         |      |      |         |           | 10 (100%) |
| Epithelium, Hyperplasia                |         |      |      |         |           | 10 (100%) |
| Epithelium, Necrosis                   |         |      |      |         | 1 (10%)   |           |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 02

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 12/09/2016

Time Report Requested: 13:55:48

First Dose M/F: 01/23/09 / 01/22/09

Lab: BAT

| B6C3F1 MICE MALE             | 0 mg/kg | 10 mg/kg | 30 mg/kg | 100 mg/kg | 300 mg/kg | 600 mg/kg |
|------------------------------|---------|----------|----------|-----------|-----------|-----------|
| <b>CARDIOVASCULAR SYSTEM</b> |         |          |          |           |           |           |
| Blood Vessel                 | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Heart                        | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>ENDOCRINE SYSTEM</b>      |         |          |          |           |           |           |
| Adrenal Cortex               | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Subcapsular, Hyperplasia     | 2 (20%) |          |          |           |           | 1 (10%)   |
| Adrenal Medulla              | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Islets, Pancreatic           | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Parathyroid Gland            | (9)     | (0)      | (0)      | (0)       | (0)       | (10)      |
| Pituitary Gland              | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Thyroid Gland                | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>GENERAL BODY SYSTEM</b>   |         |          |          |           |           |           |
| None                         |         |          |          |           |           |           |
| <b>GENITAL SYSTEM</b>        |         |          |          |           |           |           |
| Epididymis                   | (10)    | (10)     | (10)     | (10)      | (10)      | (10)      |
| Preputial Gland              | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Prostate                     | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Seminal Vesicle              | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Testes                       | (10)    | (10)     | (10)     | (10)      | (10)      | (10)      |
| <b>HEMATOPOIETIC SYSTEM</b>  |         |          |          |           |           |           |
| Bone Marrow                  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Lymph Node, Mandibular       | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Lymph Node, Mesenteric       | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 02

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 12/09/2016

Time Report Requested: 13:55:48

First Dose M/F: 01/23/09 / 01/22/09

Lab: BAT

| B6C3F1 MICE MALE                                      | 0 mg/kg | 10 mg/kg | 30 mg/kg | 100 mg/kg | 300 mg/kg | 600 mg/kg |
|---|---------|----------|----------|-----------|-----------|-----------|
| Spleen  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Thymus  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>INTEGUMENTARY SYSTEM</b>                           |         |          |          |           |           |           |
| Skin  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>MUSCULOSKELETAL SYSTEM</b>                         |         |          |          |           |           |           |
| Bone  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>NERVOUS SYSTEM</b>                                 |         |          |          |           |           |           |
| Brain   | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>RESPIRATORY SYSTEM</b>                             |         |          |          |           |           |           |
| Lung  | (10)    | (0)      | (0)      | (0)       | (1)       | (10)      |
| Serosa, Inflammation, Granulomatous                   |         |          |          |           | 1 (100%)  |           |
| Nose  | (10)    | (10)     | (10)     | (10)      | (10)      | (10)      |
| Glands, Olfactory Epithelium, Hyperplasia             |         |          |          |           |           | 7 (70%)   |
| Nerve, Atrophy  |         |          |          |           | 8 (80%)   | 10 (100%) |
| Olfactory Epithelium, Accumulation, Hyaline Droplet   |         |          |          |           | 2 (20%)   | 9 (90%)   |
| Olfactory Epithelium, Atrophy                         |         |          |          |           | 10 (100%) | 10 (100%) |
| Respiratory Epithelium, Accumulation, Hyaline Droplet | 4 (40%) | 5 (50%)  | 1 (10%)  | 5 (50%)   | 10 (100%) | 10 (100%) |
| Respiratory Epithelium, Vacuolization Cytoplasmic     | 1 (10%) | 1 (10%)  |          |           |           | 6 (60%)   |
| Trachea   | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>SPECIAL SENSES SYSTEM</b>                          |         |          |          |           |           |           |
| Eye   | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 02

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Myristicin

CAS Number: 607-91-0

Date Report Requested: 12/09/2016

Time Report Requested: 13:55:48

First Dose M/F: 01/23/09 / 01/22/09

Lab: BAT

---

| B6C3F1 MICE MALE      | 0 mg/kg | 10 mg/kg | 30 mg/kg | 100 mg/kg | 300 mg/kg | 600 mg/kg |
|-----------------------|---------|----------|----------|-----------|-----------|-----------|
| Retina, Atrophy       | 1 (10%) |          |          |           |           |           |
| Harderian Gland       | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <hr/>                 |         |          |          |           |           |           |
| URINARY SYSTEM        |         |          |          |           |           |           |
| Kidney                | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Inflammation, Chronic | 1 (10%) |          |          |           |           |           |
| Nephropathy           | 1 (10%) |          |          |           |           | 1 (10%)   |
| Urinary Bladder       | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 02

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 12/09/2016

Time Report Requested: 13:55:48

First Dose M/F: 01/23/09 / 01/22/09

Lab: BAT

| B6C3F1 MICE FEMALE                     | 0 mg/kg | 10 mg/kg | 30 mg/kg | 100 mg/kg | 300 mg/kg | 600 mg/kg |
|--|---------|----------|----------|-----------|-----------|-----------|
| <b>Disposition Summary</b>             |         |          |          |           |           |           |
| Animals Initially In Study             | 10      | 10       | 10       | 10        | 10        | 10        |
| Early Deaths                           |         |          |          |           |           |           |
| Survivors                              |         |          |          |           |           |           |
| Terminal Sacrifice                     | 10      | 10       | 10       | 10        | 10        | 10        |
| Animals Examined Microscopically       | 10      | 10       | 10       | 10        | 10        | 10        |
| <b>ALIMENTARY SYSTEM</b>               |         |          |          |           |           |           |
| Esophagus                              | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Gallbladder                            | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Intestine Large, Cecum                 | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Intestine Large, Colon                 | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Intestine Large, Rectum                | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Intestine Small, Duodenum              | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Intestine Small, Ileum                 | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Intestine Small, Jejunum               | (9)     | (0)      | (0)      | (0)       | (0)       | (10)      |
| Liver                                  | (10)    | (10)     | (10)     | (10)      | (10)      | (10)      |
| Basophilic Focus                       |         |          | 1 (10%)  |           | 1 (10%)   |           |
| Clear Cell Focus                       |         |          |          |           | 3 (30%)   | 2 (20%)   |
| Fatty Change                           |         |          |          |           |           | 10 (100%) |
| Mineralization, Focal                  |         |          | 1 (10%)  |           |           |           |
| Necrosis                               |         |          |          |           | 1 (10%)   |           |
| Centrilobular, Hepatocyte, Hypertrophy |         |          |          | 10 (100%) | 10 (100%) | 10 (100%) |
| Hepatocyte, Necrosis                   |         |          |          | 1 (10%)   | 10 (100%) | 10 (100%) |
| Oval Cell, Hyperplasia                 |         |          |          |           | 10 (100%) | 10 (100%) |
| Pancreas                               | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Salivary Glands                        | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Stomach, Forestomach                   | (10)    | (10)     | (10)     | (10)      | (10)      | (10)      |
| Inflammation, Chronic                  |         |          | 2 (20%)  | 1 (10%)   | 1 (10%)   | 3 (30%)   |
| Ulcer                                  |         |          |          | 1 (10%)   |           | 2 (20%)   |
| Epithelium, Hyperkeratosis             |         |          | 2 (20%)  | 1 (10%)   | 1 (10%)   | 3 (30%)   |
| Epithelium, Hyperplasia                |         |          | 2 (20%)  | 1 (10%)   | 1 (10%)   | 3 (30%)   |
| Epithelium, Inflammation, Suppurative  |         |          | 2 (20%)  | 1 (10%)   |           | 3 (30%)   |
| Stomach, Glandular                     | (10)    | (10)     | (10)     | (10)      | (10)      | (10)      |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 02

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 12/09/2016

Time Report Requested: 13:55:48

First Dose M/F: 01/23/09 / 01/22/09

Lab: BAT

| B6C3F1 MICE FEMALE           | 0 mg/kg | 10 mg/kg | 30 mg/kg | 100 mg/kg | 300 mg/kg | 600 mg/kg |
|------------------------------|---------|----------|----------|-----------|-----------|-----------|
| Epithelium, Atrophy          |         |          |          |           |           | 10 (100%) |
| Epithelium, Hyperplasia      |         |          |          |           |           | 10 (100%) |
| Epithelium, Necrosis         |         |          |          |           | 1 (10%)   |           |
| <b>CARDIOVASCULAR SYSTEM</b> |         |          |          |           |           |           |
| Blood Vessel                 | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Heart                        | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>ENDOCRINE SYSTEM</b>      |         |          |          |           |           |           |
| Adrenal Cortex               | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Subcapsular, Hyperplasia     | 6 (60%) |          |          |           |           | 5 (50%)   |
| Adrenal Medulla              | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Islets, Pancreatic           | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Parathyroid Gland            | (9)     | (0)      | (0)      | (0)       | (0)       | (9)       |
| Pituitary Gland              | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Thyroid Gland                | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>GENERAL BODY SYSTEM</b>   |         |          |          |           |           |           |
| None                         |         |          |          |           |           |           |
| <b>GENITAL SYSTEM</b>        |         |          |          |           |           |           |
| Clitoral Gland               | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Ovary                        | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Uterus                       | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>HEMATOPOIETIC SYSTEM</b>  |         |          |          |           |           |           |
| Bone Marrow                  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Lymph Node, Mandibular       | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 02

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: MICE/B6C3F1

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 12/09/2016

Time Report Requested: 13:55:48

First Dose M/F: 01/23/09 / 01/22/09

Lab: BAT

| B6C3F1 MICE FEMALE                                    | 0 mg/kg | 10 mg/kg | 30 mg/kg | 100 mg/kg | 300 mg/kg | 600 mg/kg |
|---|---------|----------|----------|-----------|-----------|-----------|
| Lymph Node, Mesenteric                                | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Spleen  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Thymus  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>INTEGUMENTARY SYSTEM</b>                           |         |          |          |           |           |           |
| Mammary Gland   | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Skin  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>MUSCULOSKELETAL SYSTEM</b>                         |         |          |          |           |           |           |
| Bone  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>NERVOUS SYSTEM</b>                                 |         |          |          |           |           |           |
| Brain   | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <b>RESPIRATORY SYSTEM</b>                             |         |          |          |           |           |           |
| Lung  | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Arteriole, Inflammation, Chronic                      | 1 (10%) |          |          |           |           |           |
| Nose  | (10)    | (10)     | (10)     | (10)      | (10)      | (10)      |
| Glands, Olfactory Epithelium, Hyperplasia             |         |          |          |           |           | 10 (100%) |
| Nerve, Atrophy  |         |          |          |           | 9 (90%)   | 10 (100%) |
| Olfactory Epithelium, Accumulation, Hyaline Droplet   |         | 1 (10%)  |          | 3 (30%)   | 8 (80%)   | 10 (100%) |
| Olfactory Epithelium, Atrophy                         |         |          |          |           | 10 (100%) | 10 (100%) |
| Respiratory Epithelium, Accumulation, Hyaline Droplet | 5 (50%) | 3 (30%)  | 1 (10%)  | 7 (70%)   | 10 (100%) | 10 (100%) |
| Respiratory Epithelium, Vacuolization Cytoplasmic     |         |          |          |           | 2 (20%)   | 4 (40%)   |
| Trachea   | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 99009 - 02

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Myristicin

CAS Number: 607-91-0

Date Report Requested: 12/09/2016

Time Report Requested: 13:55:48

First Dose M/F: 01/23/09 / 01/22/09

Lab: BAT

---

| B6C3F1 MICE FEMALE    | 0 mg/kg | 10 mg/kg | 30 mg/kg | 100 mg/kg | 300 mg/kg | 600 mg/kg |
|-----------------------|---------|----------|----------|-----------|-----------|-----------|
| <hr/>                 |         |          |          |           |           |           |
| SPECIAL SENSES SYSTEM |         |          |          |           |           |           |
| Eye                   | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Harderian Gland       | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| <hr/>                 |         |          |          |           |           |           |
| URINARY SYSTEM        |         |          |          |           |           |           |
| Kidney                | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |
| Urinary Bladder       | (10)    | (0)      | (0)      | (0)       | (0)       | (10)      |

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion